Trillium therapeutics logo
WebTrillium Therapeutics Logo icon format. Download PNG (68.55 KB) Page last updated on: January 8th, 2024. Categories: 🇨🇦 Canada 💊 Pharmaceuticals 🧬 Biotech. WebNov 17, 2024 · Acquisition enhances Pfizer’s Oncology portfolio with addition of next-generation, investigational immuno-therapeutics for hematological malignancies Pfizer …
Trillium therapeutics logo
Did you know?
WebTrillium Therapeutics Inc. (NASDAQ/TSX:TRIL) is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. We have a strong focus on CD47, a molecule that tumors frequently use to evade the immune system. CD47 is a protective “do not eat” signal that blocks the ability of certain immune cells to ... WebNov 18, 2024 · Pfizer has concluded the acquisition of all outstanding shares of Canadian immuno-oncology company Trillium Therapeutics for a total purchase value of nearly $2.22bn in cash.. In August, Pfizer entered a definitive agreement to acquire Trillium.. Trillium is now a completely owned Pfizer subsidiary and the deal is claimed to boost the …
WebContact Email [email protected]. Phone Number 416-595-0627. Trillium Therapeutics Inc. operates as a biopharmaceutical research and development company. … WebFunding. Trillium Therapeutics has raised a total of $46M in funding over 5 rounds. Their latest funding was raised on Sep 8, 2024 from a Post-IPO Equity round. Trillium Therapeutics is registered under the ticker NASDAQ:TSX: TRIL . Their stock opened with $13.00 in its Sep 10, 2024 IPO. Trillium Therapeutics is funded by 4 investors.
WebAug 23, 2024 · Aug 23 (Reuters) - Pfizer Inc said on Monday it would buy Canadian drug developer Trillium Therapeutics Inc in a $2.26 billion deal to strengthen its arsenal of … WebApr 8, 2024 · Cash position: Trillium completed an underwritten public stock offering on January 28, 2024, raising approximately $117 million in gross proceeds.As of March 31, …
WebDeveloping innovative therapies for the treatment of cancer. Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s two …
WebFeb 28, 2024 · Trillium is also developing two similar CD47-based therapies, TTI-621 and TTI-622, for blood cancers and disorders. TRIL is currently trading at $4.80, up $1.70 or 54.84%, on the Nasdaq. SHARE ... nu breed cds for saleWebNov 17, 2024 · Acquisition enhances Pfizer’s Oncology portfolio with addition of next-generation, investigational immuno-therapeutics for hematological malignancies Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Trillium Therapeutics, a clinical stage immuno-oncology company developing innovative therapies … nu breed breath under waterWebMar 10, 2024 · About Trillium Therapeutics. Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The Company’s two clinical … nu breed bandWebContact Email [email protected]. Phone Number 416-595-0627. Trillium Therapeutics Inc. operates as a biopharmaceutical research and development company. It focuses on the immune system and its regulation. The company specializes in the discovery and development of protein therapeutics, such as monoclonal antibodies, secreted ... nubrakes austin reviewsWebSep 16, 2024 · CAMBRIDGE, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage … nu breed cdsWebAug 23, 2024 · Published Aug. 23, 2024 9:36 a.m. PDT. Share. TORONTO -. Trillium Therapeutics Inc. has signed a deal to be bought by Pfizer Inc. in an agreement valued at US$2.26 billion. Under the plan, Pfizer ... nimby issuesnimby meaning acronym